Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Vx-001 in non-small cell lung cancer
2006-005032-25Phase 2Active
- Sponsor
- Vaxon Biotech
- Start
- Oct 2006
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of vx-001 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Vaxon Biotech. Primary endpoint: Six-month disease progression rate. Started Oct 2006; status: active.
02
Drugs
vx-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-005032-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005032-25.